A study of structural phase transitions and optoelectronic properties of perovskite-type hydride MgFeH3: ab initio calculations

WOS: 000467931300001PubMed ID: 31022707In this study, the structural phase transition and optoelectronic properties of perovskite-hydride MgFeH3 under high pressure have been performed by ab initio calculations based on GGA-PBE functional. The phase transitions were observed from the cubic structure (Pm (3) over barm) to the orthorhombic (Pmn2(1)) and (Pmmn) structure. During the phase transition, the R (3) over barm,P1, Pm and P2121(2) intermediate phases were predicted. The energy-volume (E-V) relationships show that the most stable phase is Pm (3) over barm. The lattice parameters and volume increased as based on the phase transforms. From the electronic band analysis, the MgFeH3 shows a metallic character from the cubic to orthorhombic structure. The MgFeH3 indicates the peaks at 2.67 eV (464 nm) for Pm (3) over barm phase, 5.21 eV (238 nm) for Pmn2(1) phase and 2.63 eV (471 nm) for Pmmn phase. Pm (3) over barm and Pmmn phases correspond to the visible region. The absorption peaks are getting wider and have higher magnitude from Pm (3) over barm to Pmmn phase. The optical conductivity for the cubic structure with Pm (3) over barm phase was found to be higher than orthorhombic structures with Pmn2(1), and Pmmn phases. The reflectivity maxima decrease from Pm (3) over barm to Pmn2(1)

Real-world outcomes of pazopanib in metastatic soft tissue sarcoma: a retrospective Turkish oncology group (TOG) study

Aim: Description of patient characteristics, effectiveness and safety in Turkish patients treated with pazopanib for metastatic soft tissue sarcoma (STS). Patients and methods: This multicenter study is based on retrospective review of hospital medical records of patients (≥ 18 years) treated with pazopanib for non-adipocytic metastatic STS at 37 Oncology clinics across Turkey. Objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS) and overall survival (OS) were evaluated with further analysis of data on the three most common histological subtypes (leiomyosarcoma [LMS], undifferentiated pleomorphic sarcoma [UPS], synovial sarcoma [SS]) in the cohort. Results: Data of 552 adults (57.6% women, median age: 52 years) were analyzed. DCR and ORR were 43.1% and 30.8%, respectively. Median PFS was 6.7 months and OS was 13.8 months. For LMS, UPS and SS, median PFSs were 6.1, 5.9 and 7.53 months and median OSs were 15.03, 12.87 and 12.27 months, respectively. ECOG ≥ 2 was associated with poor PFS and OS. Liver metastasis was only a factor for progression. Second-line use of pazopanib (vs. front-line) was associated with better PFS, its use beyond third line predicted worse OS. Adverse events (AE) occurred in 82.7% of patients. Most common AEs were fatigue (58.3%) and anorexia (52.3%) which were graded as ≥ 3 in 8.2% and 7.4% of patients, respectively. Conclusion: Pazopanib is effective and well-tolerated in treatment of non-adipocytic metastatic STS. Its earlier use (at second-line), good performance status may result in better outcomes. Worldwide scientific collaborations are important to gain knowledge on rarer STS subtypes by conducting studies in larger patient populations